trending Market Intelligence /marketintelligence/en/news-insights/trending/7Z_dXI6C4NcPqWtdcAu4pw2 content esgSubNav
In This List

Cambrex secures $800M in loans

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Cambrex secures $800M in loans

Cambrex Corp. entered into a credit agreement for a five-year $200 million term loan and a $600 million revolving credit facility.

Interest on the loans under the credit agreement will be calculated as either adjusted London interbank offered rate plus 1.25% to 2.00% or alternate base rate plus 0.25% to 1.00%, at Cambrex's option.

Wells Fargo Bank NA is acting as administrative agent for the credit agreement, as well as the lenders party thereto from time to time.

East Rutherford, N.J.-based life sciences company Cambrex recently completed its $252 million acquisition of Avista Pharma Solutions, a contract development, manufacturing and testing company.